Compared to 1918, Today a Death Delayed Is More Likely to Be a Life Saved

Harvard economics professor Robert Barro has a useful NBER working paper showing that lockdowns during the 1918 flu pandemic succeeded in delaying deaths by flattening the curve, but not in reducing the overall number of deaths. Some would use this paper to argue against the efficacy of the current lockdowns. But there is a key difference between now and 1918: Flattening the curve in 1918 resulted in the end in about the same deaths over the 3 year run of the virus. Flattening the curve now is likely to cut off the deaths in about a year when a vaccine comes on line. Now, a death delayed is more likely to be a life saved.

Non-pharmaceutical public-health interventions (NPIs) were measured by Markel, et al. (2007) for U.S. cities during the second wave of the Great Influenza Pandemic, September 1918-February 1919. The NPIs are in three categories: school closings, prohibitions on public gatherings, and quarantine/isolation. Although an increase in NPIs flattened the curve in the sense of reducing the ratio of peak to average deaths, the estimated effect on overall deaths is small and statistically insignificant. The likely reason that the NPIs were not more successful in curtailing mortality is that the interventions had an average duration of only around one month.

The above abstract is from the following Barro NBER working paper. (The link leads to the American Enterprise Institute version of the paper.):

Barro, Robert J. “Non-Pharmaceutical Interventions and Mortality in U.S. Cities During the Great Influenza Pandemic, 1918-1919.” National Bureau of Economic Research, Inc., Working Paper # 27049 (April 2020).

Capital-Intensive Toilet Paper Firms, Already Near Capacity, Unable to Quickly Fill 600% Surge in Demand

(p. 4) As the chief executive of a company that makes toilet paper, Joey Bergstein has been through an intense few months.

. . .

You’ve mentioned that you anticipated some demand, but nothing like what was about to come.

The week of March 8 [2020] we saw a surge in demand of somewhere between 600 and 750 percent. When you build a supply chain and package, you normally have about a 30 percent buffer to be able to meet a surge in demand. Nobody built a supply chain to be able to respond to that kind of surge in demand. So the team has been in a constant state of triage ever since, and we’re still in that.

. . .

What was it about toilet paper that made it so hard to come by?

First of all, nobody anticipated the level of stocking up you would see on toilet paper. That shocked everybody. But any of these paper businesses are very capital-intensive businesses. You only make money in that business if you’re running your machines pretty close to capacity. So when you have a big surge in demand, it’s hard to increase more than you’re already producing, because you’re generally producing pretty close to capacity. You don’t have the kind of flexibility that you would normally expect to have in another business.

For the full interview, see:

David Gelles, interviewer. “Selling 2-Ply in a Pandemic (It’s Harder Than You Think).” The New York Times, SundayBusiness Section (Sunday, June 7, 2020): 4.

(Note: ellipses, and bracketed year, added; bold in original.)

(Note: the online version of the interview has the date June 5, 2020, and the title “Selling Toilet Paper and Paper Towels During the Pandemic.” The first sentence and the bold questions are from the interviewer David Gelles. The answers after the bold questions are from the interviewee Joey Bergstein.)

“We Have to Wear Masks”

(p. D8) Some people are generous transmitters of the coronavirus; others are stingy. So-called super-spreaders seem to be particularly gifted in transmitting it, although it’s unclear whether that’s because of their biology or their behavior.

On the receiving end, the shape of a person’s nostrils and the amount of nose hair and mucus present — as well as the distribution of certain cellular receptors in the airway that the virus needs to latch on to — can all influence how much virus it takes to become infected.

A higher dose is clearly worse, though, and that may explain why some young health care workers have fallen victim even though the virus usually targets older people.

. . .

Apart from avoiding crowded indoor spaces, the most effective thing people can do is wear masks, all of the experts said. Even if masks don’t fully shield you from droplets loaded with virus, they can cut down the amount you receive, and perhaps bring it below the infectious dose.

“This is not a virus for which hand washing seems like it will be enough,” Dr. Rabinowitz said. “We have to limit crowds, we have to wear masks.”

For the full story, see:

Apoorva Mandavilli. “It’s Not Whether You Were Exposed, It’s How Much.” The New York Times (Tuesday, June 2, 2020): D8.

(Note: ellipsis added.)

(Note: the online version of the story has the date May 29, 2020, and the title “It’s Not Whether You Were Exposed to the Virus. It’s How Much.”)

Mainstream Science, and Governments, Rejected Early Evidence of Symptomless Transmission

(p. 1) MUNICH — Dr. Camilla Rothe was about to leave for dinner when the government laboratory called with the surprising test result. Positive. It was Jan. 27 [2020]. She had just discovered Germany’s first case of the new coronavirus.

But the diagnosis made no sense. Her patient, a businessman from a nearby auto parts company, could have been infected by only one person: a colleague visiting from China. And that colleague should not have been contagious.

The visitor had seemed perfectly healthy during her stay in Germany. No coughing or sneezing, no signs of fatigue or fever during two days of long meetings. She told colleagues that she had started feeling ill after the flight back to China. Days later, she tested positive for the coronavirus.

. . .

Dr. Rothe and her colleagues were among the first to warn the world. But even as evidence accumulated from other scientists, leading health officials expressed unwavering confidence that symptomless spreading was not important.

In the days and weeks to come, politicians, public health officials and rival academics disparaged or ignored the Munich team. Some actively worked to undermine the warnings at a crucial moment, as the disease was spreading unnoticed in French churches, Italian soccer stadiums and Austrian ski bars. A cruise ship, the Diamond Princess, would become a deadly harbinger of symptomless spreading.

. . .

(p. 10) Though estimates vary, models using data from Hong Kong, Singapore and China suggest that 30 to 60 percent of spreading occurs when people have no symptoms.

. . .

After two lengthy phone calls with the woman, doctors at the Robert Koch Institute were convinced that she had simply failed to recognize her symptoms. They wrote to the editor of The New England Journal of Medicine, casting doubt on Dr. Rothe’s findings.

Editors there decided that the dispute amounted to hairsplitting. If it took a lengthy interview to identify symptoms, how could anyone be expected to do it in the real world?

“The question was whether she had something consistent with Covid-19 or that anyone would have recognized at the time was Covid-19,” said Dr. Eric Rubin, the journal’s editor.

“The answer seemed to be no.”

The journal did not publish the letter. But that would not be the end of it.

. . .

On Monday, Feb. 3, the journal Science published an article calling Dr. Rothe’s report “flawed.” Science reported that the Robert Koch Institute had written to the New England Journal to dispute her findings and correct an error.

. . .

Dr. Rothe’s report quickly became a symbol of rushed research. Scientists said she should have talked to the Chinese patient herself before publishing, and that the omission had undermined her team’s work. On Twitter, she and her colleagues were disparaged by scientists and armchair experts alike.

“It broke over us like a complete tsunami,” Dr. Hoelscher said.

. . .

If Dr. Rothe’s paper had implied that governments might need to do more against Covid-19, the pushback from the Robert Koch Institute was an implicit defense of the conventional thinking.

Sweden’s public health agency declared that Dr. Rothe’s report had contained major errors. The agency’s website said, unequivocally, that “there is no evidence that people are infectious during the incubation period” — an assertion that would remain online in some form for months.

French health officials, too, left no room for debate: “A person is contagious only when symptoms appear,” a government flyer read. “No symptoms = no risk of being contagious.”

. . .

(p. 11) Dr. Rothe, . . ., was shaken. She could not understand why much of the scientific establishment seemed eager to play down the risk.

“All you need is a pair of eyes,” she said. “You don’t need rocket-science virology.”

. . .

While public health officials hesitated, some doctors acted. At a conference in Seattle in mid-February, Jeffrey Shaman, a Columbia University professor, said his research suggested that Covid-19’s rapid spread could only be explained if there were infectious patients with unremarkable symptoms or no symptoms at all.

In the audience that day was Steven Chu, the Nobel-winning physicist and former U.S. energy secretary. “If left to its own devices, this disease will spread through the whole population,” he remembers Professor Shaman warning.

Afterward, Dr. Chu began insisting that healthy colleagues at his Stanford University laboratory wear masks. Doctors in Cambridge, England, concluded that asymptomatic transmission was a big source of infection and advised local health workers and patients to wear masks, well before the British government acknowledged the risk of silent spreaders.

The American authorities, faced with a shortage, actively discouraged the public from buying masks. “Seriously people — STOP BUYING MASKS!” Surgeon General Jerome M. Adams tweeted on Feb. 29.

. . .

By the end of the month [March 2020], the U.S. Centers for Disease Control announced it was rethinking its policy on masks. It concluded that up to 25 percent of patients might have no symptoms.

Since then, the C.D.C., governments around the world and, finally, the World Health Organization have recommended that people wear masks in public.

Still, the W.H.O. is sending confusing signals. Earlier this month, Dr. Van Kerkhove, the technical lead, repeated that transmission from asymptomatic patients was “very rare.” After an outcry from doctors, the agency said there had been a misunderstanding.

“In all honesty, we don’t have a clear picture on this yet,” Dr. Van Kerkhove said. She said she had been referring to a few studies showing limited transmission from asymptomatic patients.

Recent internet ads confused the matter even more. A Google search in mid-June for studies on asymptomatic transmission returned a W.H.O. advertisement titled: “People With No Symptoms — Rarely Spread Coronavirus.”

For the full story, see:

Matt Apuzzo, Selam Gebrekidan and David D. Kirkpatrick. “How the World Missed Covid’s Symptom-Free Carriers.” The New York Times, First Section (Sunday, June 28, 2020): 1 & 10-11.

(Note: ellipses, and bracketed dates, added.)

(Note: the online version of the story was updated June 27, 2020 and has the title “How the World Missed Covid-19’s Silent Spread.”)

In Italy Regulators Ban Gelato in Cones but OK Gelato in Cups

(p. A10) Europe is lifting its lockdowns, but the new rules to battle the coronavirus are baffling Europeans as the continent goes into a familiar mode: regulatory overdrive.

. . .

When Italian beaches reopened in late May, windsurfing was allowed but tanning was banned. Except at other beaches, where it was the other way around.

. . .

In Lerici, a town of pastel houses on the Italian Riviera, Mayor Leonardo Paoletti spent months coming up with a plan.

. . .

“Where the virus is, or not, is irrelevant. What matters is that there are rules, and the job of us mayors is to enforce those rules,” Mr. Paoletti said.

Some rules confuse even the mayor. Take ice-cream cones. Rules on them vary widely across Europe. Many people don’t know whether they’re allowed or not.

In Lerici, some gelato sellers were reprimanded by a central government regional representative office for offering cones instead of only paper cups.

“I don’t see why,” said Mr. Paoletti. As far as he is concerned, ice cream can be served in cones.

“At this point, nothing makes sense to me anymore,” he said.

For the full story, see:

Margherita Stancati, and Valentina Pop. “Europe Reopens With Rules for Ice Cream in Italy, Dates in Denmark.” The Wall Street Journal (Saturday, June 10, 2020): A1 & A10.

(Note: ellipses added.)

(Note: the online version of the story has the date June 9, 2020, and the title “Moving to Reopen, Europe Goes Into Regulatory Overdrive.”)

CDC Urges Americans to Wear Masks

(p. A6) The U.S. Centers for Disease Control and Prevention urged Americans on Friday [June 12.2020] to wear masks and distance themselves from others as states reopen and large gatherings take place, including protests related to the killing of George Floyd and events tied to the presidential election.

For the full story, see:

Brianna Abbott, and Betsy McKay. “CDC Sets Guidelines For Safety In Public.” The Wall Street Journal (Saturday, June 13, 2020): A6.

(Note: bracketed date added.)

(Note: the online version of the story has the date June 12, 2020, and the title “CDC Encourages Wearing Masks, Other Coronavirus Precautions at Gatherings.” Where there is a minor difference between versions, the passage quoted follows the online version. But the online version lists McKay’s name first.)

Masks Do Not Cover Genuine Smiles

(p. D3) Women do tend to smile more than men, across age groups and ethnicities. But it’s not necessarily because they are happier; in fact, women suffer higher rates of depression. Rather, said Marianne LaFrance, a psychologist at Yale University who studies gender and nonverbal communication, women feel pressure to smile, and they can be penalized if they don’t.

“Women get completely socialized that smiling should be the default expression on their face,” said Dr. LaFrance, the author of “Why Smile? The Science Behind Facial Expressions.” “So everyone expects it, including women themselves.”

. . .

As Dr. LaFrance described it, it is the social, obligatory smile — “which is the one that women do the most,” she said — that tends to be focused on the mouth muscles, easily covered up by a medical mask. But a genuine smile, or what is know in the field as the Duchenne smile (named for Guillaume Duchenne), a French anatomist who discovered it, involves both the mouth and the eyes.

“What’s interesting,” Dr. LaForce said, is that the facial muscle engaged by a genuine smile — what’s called the orbicularis oculi — can’t be used on command.

“So will the mask stifle a smile? No. Not unless it’s a fake one,” she said.

For the full commentary, see:

Jessica Bennett. “How Emotions Play Out Behind the Masks.” The New York Times (Thursday, June 11, 2020): D3.

(Note: ellipsis added.)

(Note: the online version of the commentary has the date June 10, 2020 and has the title “Silver Lining to the Mask? Not Having to Smile”.)

The book by LaFrance, mentioned in a passage quoted above, is:

LaFrance, Marianne. Why Smile?: The Science Behind Facial Expressions. pb ed. New York: W. W. Norton & Company, 2013.

First of 300 Million Vaccine Doses Are Hoped to Be Ready by October

(p. A7) Expanding its pursuit of an inoculation against the coronavirus, the U.S. Department of Health and Human Services said on Thursday it would provide “up to $1.2 billion” to the drug company AstraZeneca to develop a potential vaccine from a laboratory at Oxford University.

The deal with AstraZeneca is the fourth and by far the largest vaccine research agreement that the department has disclosed. The money will pay for a Phase 3 clinical trial of a potential vaccine in the United States this summer with about 30,000 volunteers.

The H.H.S. statement said the agency and AstraZeneca “are collaborating to make available at least 300 million doses,” and projected that the first doses could be available as early as October [2020].

. . .

In a separate statement, AstraZeneca said it had reached agreements with several governments and other organizations to produce at least 400 million doses, had “secured manufacturing capacity for one billion doses,” and will begin its first deliveries in September [2020].

For the full story, see:

David D. Kirkpatrick. “Drugmaker Gets $1.2 Billion Grant From the U.S. to Develop a Vaccine.” The New York Times (Friday, May 22, 2020): A7.

(Note: ellipsis, and bracketed years, added.)

(Note: the online version of the story was updated June 3 [sic], 2020 and has the title “$1.2 Billion From U.S. to Drugmaker to Pursue Coronavirus Vaccine.” The online version says that the title of the New York print version was “U.S. Gives Drugmaker $1.2 Billion Grant.” The title of my National print version was “Drugmaker Gets $1.2 Billion Grant From the U.S. to Develop a Vaccine.”)

Poll Says Two-Thirds of Voters Wear Mask When Outside the House

(p. A4) . . . an overwhelming majority, 80%, feel that the country is spiraling out of control, according to a new Wall Street Journal/NBC News poll.

. . .

Roughly two-thirds of voters said they always wear a mask when they leave the house, compared with 21% who sometimes wear one and 15% who said they rarely or never do.

. . .

The Journal/NBC News poll surveyed 1,000 registered voters from May 28 through June 2. The margin of error was plus or minus 3.1 percentage points.

For the full story, see:

Michael C. Bender. “Nation Deeply Worried, Poll Finds.” The Wall Street Journal (Monday, June 8, 2020): A4.

(Note: ellipses added.)

(Note: the online version of the story has the date June 7, 2020, and has the title “Americans Are More Troubled by Police Actions in Killing of George Floyd Than by Violence at Protests, Poll Finds.” The last two sentences quoted above appear in the online, but not the print, version.)

Vaccine Progress Gives Hope That Pandemic Will Begin to End in September

(p. A1) In a medical research project nearly unrivaled in its ambition and scope, volunteers worldwide are rolling up their sleeves to receive experimental vaccines against the coronavirus — only months after the virus was identified.

Companies like Inovio and Pfizer have begun early tests of candidates in people to determine whether their vaccines are safe. Researchers at the University of Oxford in England are testing vaccines in human subjects, too, and say they could have one ready for emergency use as soon as September.

. . .

(p. A11) The coronavirus itself has turned out to be clumsy prey, a stable pathogen unlikely to mutate significantly and dodge a vaccine.

“It’s an easier target, which is terrific news,” said Michael Farzan, a virologist at Scripps Research in Jupiter, Fla.

An effective vaccine will be crucial to ending the pandemic, which has sickened at least 4.7 million worldwide and killed at least 324,000. Widespread immunity would reopen the door to lives without social distancing and face masks.

For the full story, see:

Carl Zimmer, Knvul Sheikh and Noah Weiland. “Tests Fuel Hope That Vaccine Is Months, Not Years, Away.” The New York Times (Thursday, May 21, 2020): A1 & A11.

(Note: ellipses added.)

(Note: the online version of the story was updated June [sic] 10, 2020 and has the title “A New Entry in the Race for a Coronavirus Vaccine: Hope.” The online versions says that the title of the New York print version is “Labs Step Up Race to Be First, Or Even 4th, to Find a Vaccine.” the title of my National print version was “Tests Fuel Hope That Vaccine Is Months, Not Years, Away.”)

Anti-Hydroxychloroquine Lancet Study Retracted by Authors

(p. A7) Two major studies casting doubt on the ability of antimalaria drugs to treat Covid-19 patients based on data from a little-known Chicago company, Surgisphere Corp., were retracted Thursday [June 4, 2020].

The Lancet first pulled a study published late last month that found antimalarials provided no benefit as a treatment for Covid-19 infections while increasing the risk of heart problems and death. The New England Journal of Medicine then retracted a separate article, published in early May, that examined the impact of cardiovascular and blood-pressure drugs in Covid-19 patients.

. . .

Three of the Lancet paper’s authors said they decided to retract the paper after Surgisphere refused to share the full data set as part of a review triggered by concerns raised by outside researchers. The Lancet published a correction to the study on May 29.

“We always aspire to perform our research in accordance with the highest ethical and professional guidelines,” the authors, Drs. Mehra, Patel and Frank Ruschitzka said in a statement. “We can never forget the responsibility we have as researchers to scrupulously ensure that we rely on data sources that adhere to our high standards. Based on this development, we can no longer vouch for the veracity of the primary data sources.”

. . .

Following the study, the World Health Organization paused enrolling patients in clinical trials of hydroxychloroquine, although this week the organization said it resumed the trials.

In the days following publication of the study, however, other researchers began to raise questions about the Surgisphere data, first on social media and in emails, then in an open letter to The Lancet and the study’s authors. More than 100 researchers signed on to the letter.

For the full story, see:

Jared S. Hopkins and Russell Gold. “Antimalaria Drug Studies Are Retracted.” The Wall Street Journal (Friday, June 5, 2020): A7.

(Note: ellipses, and bracketed date, added. In the passages quoted above, where the online version differs from the print version, the quoted passages follow the online version.)

(Note: the online version of the story was updated June 5, 2020, and has the title “Hydroxychloroquine Studies Tied to Data Firm Surgisphere Retracted.”)